Molecular Docking Analysis of Phytocompounds from Hyptis Verticillata as Potential Inhibitors of Human Cyclooxygenase-2 (COX-2)

Cyclooxygenase-2 (COX-2) is a key inducible enzyme in the inflammatory pathway, catalyzing the conversion of arachidonic acid into prostaglandins that mediate pain, fever, and inflammation. Selective COX-2 inhibitors such as celecoxib and rofecoxib have demonstrated strong therapeutic effects but are associated with adverse cardiovascular and gastrointestinal complications, underscoring the need for safer alternatives. Medicinal plants represent a valuable source of novel bioactive compounds with promising anti-inflammatory properties. Hyptis verticillata, a member of the Lamiaceae family, has been widely used in ethnomedicine for treating fever, colds, and inflammatory conditions, and is known to contain diverse phytochemicals including terpenoids, flavonoids, sterols, and essential oils. This study aimed to evaluate the molecular docking interactions of phytocompounds from H. verticillata with human COX-2 (PDB ID: 6COX) as potential natural anti-inflammatory agents. Seven phytochemicals reported in previous phytochemical profiling of the plant were docked against the COX-2 active site using AutoDock Vina implemented in PyRx, and their interactions compared with reference inhibitors celecoxib and rofecoxib. Binding affinities ranged from −3.7 to −8.2 kcal/mol. Squalene demonstrated the strongest affinity (−8.2 kcal/mol), comparable to rofecoxib (−8.2 kcal/mol), while aliphatic hydrocarbons such as 1-octadecyne (−6.9 kcal/mol) and 1-fluorodecane (−6.1 kcal/mol) showed moderate activity. Celecoxib, unexpectedly scoring −3.7 kcal/mol, highlighted potential docking protocol limitations that warrant revalidation. Interaction analysis revealed that hydrophobic contacts dominated ligand binding, consistent with the structural hydrophobicity of the COX-2 catalytic tunnel. Although squalene showed high docking affinity, ADMET predictions indicated poor solubility and oral bioavailability, limiting its drug-likeness. In contrast, smaller hydrocarbons displayed more favorable pharmacokinetic profiles but weaker binding energies. These findings suggest that H. verticillata harbors compounds with structural potential for COX-2 inhibition, though optimization and experimental validation are required. The study provides a computational foundation for developing safer plant-derived anti-inflammatory agents.

Hyptis verticillata, cyclooxygenase-2, molecular docking, phytochemicals, anti-inflammatory, ADMET

1. Adesina, S. K. (1982). Studies on some plants used as anticonvulsants in American and African traditional medicine. Fitoterapia, 53(2), 147–162. [Google Scholar] [Crossref]

2. Ajiboye, B. O., Olayemi, I. K., & Ojo, O. A. (2018). Gas chromatography–mass spectrometry (GC–MS) analysis of Hyptis verticillata (Jacq.) leaves cultivated in Nigeria. International Journal of Biological and Chemical Sciences, 12(3), 1349–1356. [Google Scholar] [Crossref]

3. Chandrasekharan, N. V., Dai, H., Roos, K. L., Evanson, N. K., Tomsik, J., Elton, T. S., & Simmons, D. L. (2002). COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs. Proceedings of the National Academy of Sciences, 99(21), 13926–13931. [Google Scholar] [Crossref]

4. Daina, A., Michielin, O., & Zoete, V. (2017). SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific Reports, 7, 42717. [Google Scholar] [Crossref]

5. Daina, A., Michielin, O., & Zoete, V. (2017). SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness, and medicinal chemistry friendliness of small molecules. Scientific Reports, 7, 42717. [Google Scholar] [Crossref]

6. Hinz, B., & Brune, K. (2002). Cyclooxygenase-2—10 years later. Journal of Pharmacology and Experimental Therapeutics, 300(2), 367–375. [Google Scholar] [Crossref]

7. Kitchen, D. B., Decornez, H., Furr, J. R., & Bajorath, J. (2004). Docking and scoring in virtual screening for drug discovery: Methods and applications. Nature Reviews Drug Discovery, 3(11), 935–949. [Google Scholar] [Crossref]

8. Kitchen, D. B., Decornez, H., Furr, J. R., & Bajorath, J. (2004). Docking and scoring in virtual screening for drug discovery: Methods and applications. Nature Reviews Drug Discovery, 3(11), 935–949. [Google Scholar] [Crossref]

9. Kurumbail, R. G., Stevens, A. M., Gierse, J. K., McDonald, J. J., Stegeman, R. A., Pak, J. Y., … Stallings, W. C. (1996). Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature, 384(6610), 644–648. [Google Scholar] [Crossref]

10. Kurumbail, R. G., Stevens, A. M., Gierse, J. K., McDonald, J. J., Stegeman, R. A., Pak, J. Y., … & Stallings, W. C. (1996). Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature, 384(6610), 644–648. [Google Scholar] [Crossref]

11. Lans, C. (2006). Ethnomedicines used in Trinidad and Tobago for reproductive problems. Journal of Ethnobiology and Ethnomedicine, 2, 9. [Google Scholar] [Crossref]

12. Medzhitov, R. (2008). Origin and physiological roles of inflammation. Nature, 454(7203), 428–435. [Google Scholar] [Crossref]

13. Mukherjee, D., Nissen, S. E., & Topol, E. J. (2001). Risk of cardiovascular events and rofecoxib: Cumulative meta-analysis. The Lancet, 358(9299), 1272–1273. https://doi.org/10.1016/S0140-6736(01)06425-1 [Google Scholar] [Crossref]

14. Rouzer, C. A., & Marnett, L. J. (2009). Cyclooxygenases: Structural and functional insights. Journal of Lipid Research, 50(Supplement), S29–S34. [Google Scholar] [Crossref]

15. Smith, W. L., DeWitt, D. L., & Garavito, R. M. (2000). Cyclooxygenases: Structural, cellular, and molecular biology. Annual Review of Biochemistry, 69(1), 145–182. https://doi.org/10.1146/annurev.biochem.69.1.145 [Google Scholar] [Crossref]

16. Wang, J. L., Limburg, D., Graneto, M. J., Springer, J., Hamper, J. R., Liao, S., … Carter, J. (2010). The novel benzopyran class of selective cyclooxygenase-2 inhibitors. Bioorganic & Medicinal Chemistry Letters, 20(24), 7159–7163. https://doi.org/10.1016/j.bmcl.2010.09.128 [Google Scholar] [Crossref]

17. Zarghi, A., & Arfaei, S. (2011). Selective COX-2 inhibitors: A review of their structure–activity relationships. Iranian Journal of Pharmaceutical Research, 10(4), 655–683. https://doi.org/10.22037/IJPR.2011.1027 [Google Scholar] [Crossref]

• "Towards GDP to GEP-Centric Model: A Proposed GEP Index Framework and Its Application in Haryana"
• Physicochemical Analysis of Petroleum Products in Selected Depots in Calabar Metropolis Cross River State and The Effects on Motor Engine
• Impact of Employee Welfare Measures on Workforce Well-Being in SBI: Insights from the Public Banking Sector
• Problem of Small-Scale Farmers in Agricutlure Sector in Tirunelveli Taluk
• Globalization, Economic Development, and Ecological Footprint in Tunisia: A QARDL Approach